Crohn和Colitis基金会在Palisade Bio投资高达50万美元, 以推广有前途的口服药物, 治疗严重的炎症肠病。 The Crohn’s & Colitis Foundation invested up to $500,000 in Palisade Bio to advance a promising oral drug for severe inflammatory bowel diseases.

Palisade Bio从Crohn & Colitis Foundation的IBD风险投资公司IBD Ventures(IBD Ventures PALI-2108)获得高达500 000美元的战略股权投资, Palisade Bio received a strategic equity investment of up to $500,000 from the Crohn’s & Colitis Foundation’s IBD Ventures program to advance PALI-2108, a once-daily oral PDE4 inhibitor prodrug targeting fibrostenotic Crohn’s disease and moderate to severe ulcerative colitis. 该药物在两种条件下都完成了第1a和第1b阶段的试验,目前正在进行第1b阶段对Crohn的纤维化疾病的研究。 The drug has completed Phase 1a and 1b trials in both conditions, with ongoing Phase 1b studies in fibrostenotic Crohn’s disease. 该公司的股份在新闻上上升了1.6 % , 反映出对治疗解决未满足医疗需求的潜力的乐观情绪。 The company’s shares rose 1.6% on the news, reflecting optimism over the treatment’s potential to address unmet medical needs.